→ No longer content to pick off 1 drug at a time for his growing stable of companies, Roivant chief Vivek Ramaswamy has struck a deal that gives him options on a slate of programs in development at Daiichi Sankyo. And he can use these new drugs to seed the pipelines of his future startups.
→ At a time high insulin prices have become a lightning rod issue in the US, Novartis is teaming up with China’s Gan & Lee to provide cheaper knockoffs of three big brands.
→ Despite encouraging data from a tiny open-label trial showing its oral complement inhibitor could stand on its own as a treatment for paroxysmal nocturnal haemoglobinuria, Achillion Pharmaceuticals is halting this particular program in face of Alexion’s continued dominance in the field. The company is however keeping ACH-4471 in PNH patients not responding to Soliris, and as monotherapy in another disease known as C3 glomerulopathy. There’s also the next-gen, though earlier stage, candidate ACH-5228, which execs hope would prove more competitive against Soliris.
→ Ziopharm and the cell therapy company TriArm, formed by a fund managed by Kleiner Perkins managing partner James Huang, have formed a new company to lead the development and commercialization of “Sleeping Beauty-generated CAR-T therapies.” TriArm is committing up to $35 million to the venture.
→ Betting on the RIG-I pathway in immunotherapy, Pfizer $PFE is getting its hands on Kineta’s screening platform as well as related compounds and technologies. Kineta, which is receiving $15 million upfront for the deal plus $505 million in potential milestones, will conduct target-related research funded by the pharma giant for three years, after which Pfizer will take over development and commercialization.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.Free Subscription